In 2021, the cardiac biomarkers industry contributes $8,459.6 million, and it is projected to rise at a rate of 10.5%, to capture $20,718.8 million revenue in 2030. It is led by the rising prevalence of acute coronary syndrome, increasing point-of-care testing kit demand, and technological advancements in the industry. Moreover, the surging investments in biomarker research, increasing CVDs incidences, and … Continua a leggere→